— Arbutus Biopharma Corporation (NASDAQ:ABUS) reported a net loss of $164.9 million or $2.89 per share for fiscal 2019, compared to a loss of $67.2 million or $1.21 per share last year.
— Total revenues edged up to $6.01 million from $5.9 million in 2018
— Research and development expenses were almost unchanged year-over-year at $57.6 million in fiscal 2019
— Achieved progress in a focused discovery effort on follow-on compounds for the current HBV pipeline
— On track to advance a next-generation oral HBV specific RNA-destabilizer with chemical scaffolds distinct from AB-452 through lead optimization
— Ended 2019 with $90.8 million in cash, cash equivalents and short-term investments
— Expects to utilize between $54 to $58 million of cash and investments to fund operations in 2020
Most Popular
Verizon Communications (VZ) Q1 2024 Earnings: Key financials and quarterly highlights
Verizon Communications Inc. (NYSE: VZ) reported first quarter 2024 earnings results today. Total operating revenue was $33 billion, up 0.2% from the same period last year. Net income attributable to
NextTrip stands out as one of the most descriptive names in travel sector: CEO
NextTrip, Inc. (NASDAQ: NTRP) is a technology-driven travel agency that offers travel booking and interactive travel media solutions. The online platform allows travelers to book accommodation and transportation services including
What to look for when American Airlines (AAL) reports Q1 2024 earnings results
Shares of American Airlines Group Inc. (NASDAQ: AAL) rose 1% on Friday. The stock has gained over 3% over the past three months. The airline is scheduled to report its first
